Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
2.
Stem Cell Reports ; 18(3): 613-617, 2023 03 14.
Artigo em Inglês | MEDLINE | ID: mdl-36827977

RESUMO

We outlined five studies regarding the quality of the review by committees based on the Act on the Safety of Regenerative Medicine. The findings raise serious concerns about the independence, integrity, and quality of reviews of therapeutic plans by these committees with inappropriately close relationships to medical institutions and companies.


Assuntos
Medicina Regenerativa , Japão
3.
PLoS One ; 9(1): e84998, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-24416332

RESUMO

INTRODUCTION: International norms and ethical standards have suggested that compensation for research-related injury should be provided to injured research volunteers. However, statistical data of incidence of compensation claims and the rate of awarding them have been rarely reported. METHOD: Questionnaire surveys were sent to pharmaceutical companies and medical institutions, focusing on industry-initiated clinical trials aiming at new drug applications (NDAs) on patient volunteers in Japan. RESULTS: With the answers from pharmaceutical companies, the incidence of compensation was 0.8%, including 0.06% of monetary compensation. Of the cases of compensation claims, 99% were awarded. In turn, with the answers from medical institutions, the incidence of compensation was 0.6%, including 0.4% of serious but not death cases, and 0.04% of death cases. Furthermore, most claims for compensation were initiated by medical institutions, rather than by the patients. On the other hand, with the answers from clinical trial volunteers, 3% of respondents received compensations. These compensated cases were 25% of the injuries which cannot be ruled out from the scope of compensation. CONCLUSION: Our study results demonstrated that Japanese pharmaceutical companies have provided a high rate of compensation for clinical trial-related injuries despite the possibility of overestimation. In the era of global clinical development, our study indicates the importance of further surveys to find each country's compensation policy by determining how it is being implemented based on a survey of the actual status of compensation coming from statistical data.


Assuntos
Compensação e Reparação , Indústria Farmacêutica/economia , Voluntários Saudáveis/legislação & jurisprudência , Revisão da Utilização de Seguros/economia , Ferimentos e Lesões/economia , Ensaios Clínicos como Assunto , Indústria Farmacêutica/ética , Indústria Farmacêutica/estatística & dados numéricos , Drogas em Investigação/efeitos adversos , Humanos , Revisão da Utilização de Seguros/ética , Revisão da Utilização de Seguros/estatística & dados numéricos , Japão , Inquéritos e Questionários , Ferimentos e Lesões/induzido quimicamente
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...